Drugs / MEDI9253
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04613492 | Dec 2020 → May 2024 | cancer | AstraZeneca | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEDI9253 | “Participants will receive either single or multiple dose of MEDI9253; sequentially or concurrent with Durvalumab” NCT04613492 ↗ |
| Route | Intravenous | “Participants will receive intravenous (IV) infusion of a single dose of MEDI9253 dose level 1 on Day 1” NCT04613492 ↗ |